CLINICAL_TRIALS
trial_result
· 2024-05-14
Clinical Trial Update: A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 2]
Summary
A Phase 2 clinical trial evaluating HYML-122 for FLT3-positive relapsed or refractory acute myeloid leukemia is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tarapeutics Science Inc. | Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Status: RECRUITING